Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
24.92
-0.03 (-0.12%)
Aug 21, 2026, 4:00 PM EDT - Market closed
Denali Therapeutics Stock Forecast
Stock Price Forecast
According to 20 analysts polled by S&P Global, Denali Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $35.44. The average 1-year stock price forecast is 42.22% higher than the current stock price, while the lowest is $27 (+8.35%) and the highest is $42 (+68.54%).
Price Target: $35.44 (+42.22%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Denali Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 17 | 17 | 17 | 17 | 17 | 17 |
| Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 19 | 19 | 19 | 20 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| J.P. Morgan | J.P. Morgan | Buy Maintains $29 | Buy | Maintains | $29 | +16.37% | Aug 11, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $42 | Buy | Maintains | $42 | +68.54% | Aug 7, 2026 |
| UBS | UBS | Buy Reiterates $25 → $34 | Buy | Reiterates | $25 → $34 | +36.44% | Aug 7, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Reiterates $36 → $40 | Buy | Reiterates | $36 → $40 | +60.51% | Aug 7, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Reiterates $41 | Buy | Reiterates | $41 | +64.53% | Aug 7, 2026 |
Financial Forecast
Revenue This Year
60.84M
Revenue Next Year
129.18M
from 60.84M
Increased by 112.31%
EPS This Year
-2.29
from -2.97
EPS Next Year
-2.43
from -2.29
EPS and Forward PE are based on non-GAAP adjusted numbers.